Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis

Kyverna Therapeutics, Inc.

Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.
Conference call held same day at 8 a.m. Eastern Time to discuss results; slides furnished as Exhibit 99.1.
No specific efficacy or safety figures included in the filing text; detailed data in attached slide deck.
Kyverna is a clinical-stage biotech focused on CAR T-cell therapies for autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.